公开(公告)号：US07081241B1

公开(公告)日：2006-07-25

申请号：US09167705

申请日：1998-10-06

申请人： Ann Marie Schmidt ,  David Stern

发明人： Ann Marie Schmidt ,  David Stern

IPC分类号： A61K39/395

CPC分类号： A61K38/1703 ,  A01K2217/05 ,  C07K14/70503

摘要： The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

摘要翻译： 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法，其包括：（a）混合：（i）RAGE肽或sRAGE肽或 片段，（ii）EN-RAGE肽或其片段，和（iii）化合物; （b）测量步骤（a）（i）的肽与步骤（a）（ii）的肽之间的相互作用水平，和（c）将步骤（b）中所发生的相互作用的量与测量的量进行比较 在步骤（a）（i）的肽和步骤（a）（ii）的肽之间，在不存在化合物的情况下，确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用 其中在化合物存在下相互作用量的减少表明该化合物能够抑制相互作用。 本发明还提供了一种抑制受试者的炎症的方法，其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物（RAGE）的相互作用，从而抑制受试者的炎症 学科。

公开(公告)号：US20060134073A1

公开(公告)日：2006-06-22

申请号：US11173537

申请日：2005-07-01

申请人： Yoshifumi Naka ,  David Pinsky ,  David Stern

发明人： Yoshifumi Naka ,  David Pinsky ,  David Stern

IPC分类号： C12N5/08 ,  A61K35/14 ,  A61K31/7076 ,  A61K31/52

CPC分类号： A61K35/44 ,  C12N5/0691 ,  Y02A50/395

摘要： The present invention relates to ex vivo methods for preserving/maintaining blood vessels that are to be used as vascular grafts. The present invention also relates to compositions comprising an analogue of cAMP and/or an analogue of cGMP for use in the methods of the invention, which compositions are free of: (i) an inhibitor of Type I phosphodiesterase, (ii) an inhibitor of Type II phosphodiesterase, (iii) an inhibitor of Type III phosphodiesterase, (iv) an inhibitor of Type IV phosphodiesterase, and (v) an inhibitor of TNF-α.

摘要翻译： 本发明涉及用于保存/维持用作血管移植物的血管的离体方法。 本发明还涉及包含用于本发明方法的cAMP类似物和/或cGMP类似物的组合物，该组合物不含：（i）I型磷酸二酯酶抑制剂，（ii） II型磷酸二酯酶，（iii）III型磷酸二酯酶抑制剂，（iv）IV型磷酸二酯酶抑制剂，和（v）TNF-α抑制剂。

公开(公告)号：US06973588B2

公开(公告)日：2005-12-06

申请号：US10306527

申请日：2002-11-27

申请人： Dana C. DeMeo ,  David Stern ,  Thomas Wulff

发明人： Dana C. DeMeo ,  David Stern ,  Thomas Wulff

IPC分类号： G06F1/16 ,  G06F11/00 ,  H02H3/05 ,  H04L1/22

CPC分类号： G06F1/1632 ,  G06F1/1626 ,  G06F1/1684 ,  G06F2200/1632

摘要： An architecture for updating corrupted instructions in a computing device. The computing device includes a housing for enclosing a flash memory for storing a boot loader routine, and at least one boundary-scan device internal to the computing device for processing the boot loader routine, and operatively disposed on a boundary-scan bus. The housing includes a boundary-scan port through which updated instructions are communicated and power provided. The port is concealed under a label, cover, or in a location that limits access by the device owner, such as the battery well.

摘要翻译： 用于更新计算设备中的损坏指令的架构。 计算设备包括用于封装用于存储引导加载程序的闪存的外壳，以及用于处理引导加载程序的计算设备内部的至少一个边界扫描设备，并且可操作地设置在边界扫描总线上。 外壳包括边界扫描端口，通过该边界扫描端口更新了指令并提供了电源。 该端口被隐藏在标签，盖子或限制设备所有者访问的位置，例如电池井。

公开(公告)号：US20050065912A1

公开(公告)日：2005-03-24

申请号：US10653307

申请日：2003-09-02

申请人： Charles Cafrelli ,  David Stern ,  F. Emerson

发明人： Charles Cafrelli ,  David Stern ,  F. Emerson

IPC分类号： G06F17/30 ,  G06F7/00

CPC分类号： G11B27/34 ,  G06F16/48 ,  G11B27/002 ,  G11B27/11 ,  G11B2220/2545 ,  G11B2220/2562 ,  G11B2220/41

摘要： A digital media system includes a changer control system that controls an optical disc changer. The changer control system includes a local database of metadata records containing information regarding the optical discs in the optical disc changer. The changer control system is also networked to a digital media server that stores digital media files. The digital media server includes a remote database of metadata records containing information regarding the digital media files. The changer control system provides a user interface that allows a user to access information regarding both the optical discs in the optical disc changer and the digital media files stored in the digital media server. To provide this information, a file system of the changer control system creates a merged set of selected metadata records from the local database and the remote database, in response to a request from the user interface.

摘要翻译： 数字媒体系统包括控制光盘更换器的变换器控制系统。 更换器控制系统包括包含关于光盘更换器中的光盘的信息的元数据记录的本地数据库。 更换器控制系统还与存储数字媒体文件的数字媒体服务器联网。 数字媒体服务器包括元数据记录的远程数据库，其中包含有关数字媒体文件的信息。 更换器控制系统提供用户界面，其允许用户访问关于光盘更换器中的光盘和存储在数字媒体服务器中的数字媒体文件的信息。 为了提供该信息，更改器控制系统的文件系统响应于来自用户界面的请求，从本地数据库和远程数据库创建合并的一组选定的元数据记录。

公开(公告)号：US20050048133A1

公开(公告)日：2005-03-03

申请号：US10679135

申请日：2003-10-03

申请人： David Pinsky ,  David Stern ,  Charles Prestigiacome

发明人： David Pinsky ,  David Stern ,  Charles Prestigiacome

IPC分类号： A61K38/00 ,  A61K38/48 ,  C07K14/705 ,  C07K16/28 ,  C12N9/64 ,  A61K33/00

CPC分类号： C12N9/644 ,  A61K38/4846 ,  C07K14/70564 ,  C07K16/2854 ,  C12Y304/21022

摘要： The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

摘要翻译： 本发明提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内以足够量的时间向所述受试者施用药学上可接受的形式的选择素拮抗剂，以防止白血细胞积聚，从而治疗缺血性 主题无序。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内向受试者施用足够量的一氧化碳气体，从而治疗受试者的缺血性疾病。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法，其包括在足够的时间内以足够的时间向受试者施用药学上可接受的形式的灭活因子IX以抑制凝血，以便治疗缺血性障碍 学科。

公开(公告)号：USD486613S1

公开(公告)日：2004-02-10

申请号：US29179666

申请日：2003-04-14

申请人： Jules Stern ,  David Stern ,  Kenneth Stern ,  Peter Stankus

设计人： Jules Stern ,  David Stern ,  Kenneth Stern ,  Peter Stankus

公开(公告)号：US06670136B2

公开(公告)日：2003-12-30

申请号：US09826589

申请日：2001-04-05

申请人： Ann Marie Schmidt ,  David Stern

发明人： Ann Marie Schmidt ,  David Stern

IPC分类号： G01N3353

CPC分类号： C07K14/70503 ,  A01K2217/05 ,  A61K38/00

摘要： The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

摘要翻译： 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法，其包括：（a）混合：（i）RAGE肽或sRAGE肽或 片段，（ii）EN-RAGE肽或其片段，和（iii）化合物; （b）测量步骤（a）（i）的肽与步骤（a）（ii）的肽之间的相互作用水平，和（c）将步骤（b）中所发生的相互作用的量与测量的量进行比较 在不存在化合物的情况下，步骤（a）（i）的petpide和步骤（a）（ii）的肽之间，从而确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用 其中在化合物存在下相互作用量的减少表明该化合物能够抑制相互作用。 本发明还提供了一种抑制受试者的炎症的方法，其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物（RAGE）的相互作用，从而抑制受试者的炎症 学科。

公开(公告)号：US06586750B2

公开(公告)日：2003-07-01

申请号：US09922492

申请日：2001-08-03

申请人： Jean I. Montagu ,  David Stern

发明人： Jean I. Montagu ,  David Stern

IPC分类号： G01N2164

CPC分类号： G01N21/6452 ,  G01N21/6456

摘要： An optical scanning system for examining material associated with a substrate includes at least one scanning module for displacing two or more objective lenses, at least one optical coupling system and a translation system. The two objective lenses are mounted on one or more scan arms and are constructed to scan over regions or subregions associated with the substrate. The scanning module is configured to displace the scan arm(s) to perform the scan and thereby displace the two objective lenses. Each objective lens is arranged to deliver light to the material and collect light from the material.

公开(公告)号：US06555340B1

公开(公告)日：2003-04-29

申请号：US09263312

申请日：1999-03-05

申请人： Ann Marie Schmidt ,  David Stern

发明人： Ann Marie Schmidt ,  David Stern

IPC分类号： C12P2106

CPC分类号： A61K38/1703 ,  A01K2217/05 ,  C07K14/70503

摘要： The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

摘要翻译： 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法。 本发明还提供了一种抑制受试者的炎症的方法，其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物（RAGE）的相互作用，从而抑制受试者的炎症 学科。

公开(公告)号：US06480324B2

公开(公告)日：2002-11-12

申请号：US09880058

申请日：2001-06-14

申请人： Calvin F. Quate ,  David Stern

发明人： Calvin F. Quate ,  David Stern

IPC分类号： G02B2608

CPC分类号： G03F7/70291 ,  B01J19/0046 ,  B01J2219/00353 ,  B01J2219/00439 ,  B01J2219/00527 ,  B01J2219/00529 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00596 ,  B01J2219/00605 ,  B01J2219/00608 ,  B01J2219/00612 ,  B01J2219/00617 ,  B01J2219/00626 ,  B01J2219/00637 ,  B01J2219/00659 ,  B01J2219/00689 ,  B01J2219/00711 ,  B01J2219/00722 ,  B01J2219/00725 ,  B82Y30/00 ,  C40B40/06 ,  C40B60/14 ,  G03F7/70283 ,  G03F7/704

摘要： An improved optical photolithography system and method provides predetermined light patterns generated by a direct write system without the use of photomasks. The Direct Write System provides predetermined light patterns projected on the surface of a substrate (e.g., a wafer) by using a computer controlled component for dynamically generating the predetermined light pattern, e.g., a spatial light modulator. Image patterns are stored in a computer and through electronic control of the spatial light modulator directly illuminate the wafer to define a portion of the polymer array, rather than being defined by a pattern on a photomask. Thus, in the Direct Write System each pixel is illuminated with an optical beam of suitable intensity and the imaging (printing) of an individual feature is determined by computer control of the spatial light modulator at each photolithographic step without the use of a photomask. The Direct Write System including a spatial light modulator is particularly useful in the synthesis of DNA arrays and provides an efficient element for polymer array synthesis by using spatial light modulators to generate a predetermined light pattern that defines the image patterns of a polymer array to be deprotected.

摘要翻译： 改进的光学光刻系统和方法提供由直接写入系统产生的预定光图案，而不使用光掩模。 直接写入系统通过使用用于动态生成预定光图案的计算机控制部件（例如空间光调制器）来提供投影在基板（例如，晶片）的表面上的预定光图案。 图像图案存储在计算机中，并且通过空间光调制器的电子控制直接照亮晶片以限定聚合物阵列的一部分，而不是由光掩模上的图案限定。 因此，在直写系统中，每个像素用适当强度的光束照射，并且通过在每个光刻步骤的计算机控制空间光调制器而不使用光掩模来确定单个特征的成像（打印）。 包括空间光调制器在内的直接写入系统在DNA阵列的合成中特别有用，并且通过使用空间光调制器产生限定要去保护的聚合物阵列的图像图案的预定光图案，为聚合物阵列合成提供有效元素 。